EC RESPONSE TO CORONAVIRUS
European Commission responded to COVID-19 pandemic with a number of initiatives. The most important of these are summarised below. However, you can check the European Research Area (ERA) corona platform for information on related research & innovation!
An emergency call “SC1-PHE-CORONAVIRUS-2020: Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic” was announced on Jan 30, 2020. Original budget for this call was 10m which was subsequently increased up to €48.5 million. CALL LINK.
This call was closed on Feb 2020 and results came out on March 6. Initially 17 projects were selected and one more was added late March. See here and Attachment for the list of projects.
This was a very specific and targeted call mainly to scientific teams that had already been working in solutions. There were no Turkish institutions in this first call.
In addition to the above, the Innovative Medicines Initiative (IMI), a public-private partnership between the European Commission and the pharmaceutical industry, has launched a fast-track call for research proposals to develop treatments and diagnostics in response to the COVID-19 outbreak.
IMI2 – Call 20 was dedicated to Covid-19: Development of therapeutics and diagnostics combatting coronavirus infections. This call opened on Mar 3 and closed on Mar 31. Fast Track Procedure. 144 proposals submitted.
There are 4 more IMI2 Open calls that are relevant to Health and medicine community. Although not explicitly dedicated to Covid-19 they do cover main aspects like digital health information, vaccine acceleration and more (All open calls of IMI2 are here).
This round closed on Mar 20, but call is recurrent so there will be next opportunities in Jun and Nov. (See here)
There are also plenty of other initiatives announced almost every day. These initiatives come from projects/consortia that have already received funding and call for further collaboration or sub-grants (Cascading funding). For instance: Exscalate4CoV (E4C) invites collaboration to screen potential drugs, or this initiative from Robotic Alliance (Here).
Last but not least, almost all call deadlines were extended. See all these extensions here.